A Phase IB Trial of Selinexor in Combination With Immune Checkpoint Blockade in Patients With Advanced Renal Cell Carcinoma is a research paper published in Cancer Medicine (2025). On theSindex it has a DataRank of 0.212. It has been cited 3 times, with 3 citing works in its 1-hop citation network.
Scored on demand from live citation data
Linked data & code
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.208
From this paper's citation signal
Citation Network Contribution
3.78 × 10⁻³
From 1 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 3 citers.
NCI NIH HHS
Grant: GrantP30CA016672
National Institutes of Health
Grant: 3P30CA016672-41S4
Cancer Center Support (CORE) Grant
Karyopharm Therapeutics
FWCI
1.27
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals